Thursday, October 15, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 19, 2026

Crypto Casino No Deposit Bonus 2026: BitStarz Launches 50 Free Spins with Code “BIGWIN50” and Sub-10 Minute Payouts

View original at globenewswire.com
Crypto Casino No Deposit Bonus 2026: BitStarz Launches 50 Free Spins with Code “BIGWIN50” and Sub-10 Minute Payouts New York City, NY, March 19, 2026 (GLOBE NEWSWIRE) -- As more players turn to crypto casino no deposit bonus offers, concerns about payout restrictions and usability are becoming more common…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • BitStarz enables withdrawals that are often processed in under 10 minutes

    60% confidence

  • Most withdrawals are processed within 10 minutes after approval using an automated system

    60% confidence

  • BitStarz offers 50 free spins without a deposit using the new promo code BIGWIN50

    60% confidence

Data points we hold from this source

BitStarz Casino · cashout cap no deposit100 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Crypto Casino No Deposit Bonus 2026: BitStarz Launches 50 Free Spins with Code “BIGWIN50” and Sub-10 Minute Payouts — Source | Via News | Via News